User profiles for Martin Smoragiewicz
 | Martin SmoragiewiczAssistant Professor of Medicine, University of Toronto Verified email at sunnybrook.ca Cited by 2011 |
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving
past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-…
past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-…
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated …
…, S Srinivas, SK Pal, T Yuasa, M Smoragiewicz… - The lancet …, 2015 - thelancet.com
Background Previous prognostic models for second-line systemic therapy in patients with
metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We …
metastatic renal cell carcinoma have not been studied in the setting of targeted therapy. We …
CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response
D Biasci, M Smoragiewicz… - Proceedings of the …, 2020 - National Acad Sciences
Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1
T cell checkpoint induces T cell infiltration and anticancer responses in murine and human …
T cell checkpoint induces T cell infiltration and anticancer responses in murine and human …
Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy
Background Neutrophil-to-lymphocyte ratio (NLR), if elevated, is associated with worse
outcomes in several malignancies. Objective Investigation of NLR at baseline and during therapy …
outcomes in several malignancies. Objective Investigation of NLR at baseline and during therapy …
Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth …
…, SA North, CK Kollmannsberger, M Smoragiewicz… - Cancer, 2016 - Wiley Online Library
BACKGROUND Vascular endothelial growth factor (VEGF)–targeted therapies are standard
treatment for metastatic renal cell carcinoma (mRCC); however, toxicities can lead to drug …
treatment for metastatic renal cell carcinoma (mRCC); however, toxicities can lead to drug …
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies
Background It is unknown whether lymph node metastases (LNM) and their localization
negatively affect clinical outcome in metastatic renal cell carcinoma (mRCC) patients. Objective …
negatively affect clinical outcome in metastatic renal cell carcinoma (mRCC) patients. Objective …
A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study
The PI3K/AKT/mTOR pathway activation plays a central role in glioblastoma multiforme (GBM)
development and progression, and in resistance to anti-cancer therapies. Inhibition of the …
development and progression, and in resistance to anti-cancer therapies. Inhibition of the …
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study …
This multicenter phase Ib study aimed to establish a recommended phase II dose for durvalumab
(Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy…
(Du) ± tremelimumab (Tr) in combination with standard platinum-doublet chemotherapy…
[HTML][HTML] Population-based study of docetaxel or abiraterone effectiveness and predictive markers of progression free survival in metastatic castration-sensitive prostate …
Background Both Docetaxel (DOC) and Abiraterone (ABI) improve the survival of men with
metastatic, castration sensitive prostate cancer (mCSPC). However, the outcome among …
metastatic, castration sensitive prostate cancer (mCSPC). However, the outcome among …
Complementary medicine use amongst patients with metastatic cancer enrolled in phase III clinical trials
JC Wells, A Sidhu, K Ding, M Smoragiewicz… - The …, 2022 - academic.oup.com
Background Complementary medicines (CM) are frequently used by patients with cancer.
Controversy exists over the effectiveness and risk that CM may add to conventional cancer …
Controversy exists over the effectiveness and risk that CM may add to conventional cancer …